methoxyhydroxyphenylglycol has been researched along with n-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2,3-dimethoxybenzamide in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baumann, P; Hertel, A; Kehr, J; Kiessling, B; Mathé, AA; Nikisch, G; Piel, M; Reinert, M; Roesch, F; Schneider, P; Weisser, H; Wiedemann, G | 1 |
1 trial(s) available for methoxyhydroxyphenylglycol and n-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2,3-dimethoxybenzamide
| Article | Year |
|---|---|
Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first-episode schizophrenia treated with quetiapine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Antipsychotic Agents; Benzamides; Biogenic Monoamines; Brain Mapping; Dibenzothiazepines; Fluorine Radioisotopes; Homovanillic Acid; Humans; Magnetic Resonance Imaging; Male; Methoxyhydroxyphenylglycol; Middle Aged; Pilot Projects; Positron-Emission Tomography; Protein Binding; Pyrrolidines; Quetiapine Fumarate; Receptors, Dopamine D2; Schizophrenia; Tritium; Young Adult | 2010 |